The board of directors (the " Board ") of Hansoh Pharmaceutical Group Company Limited announced that HS-10517 tablets, a Category 1 innovative drug and oral small molecule 3CL protease inhibitor against SARS-CoV-2, for which the Group holds license from Beijing Huayi Health Drug Discovery Institute (also known as the Global Health Drug Discovery Institute, ("GHDDI")), has been granted a clinical trial approval issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of adult patients with mild to moderate SARS-CoV-2 infection. As disclosed in the announcement of the Company dated August 22, 2022, Hansoh (Shanghai) Healthtech Company Limited, a subsidiary of the Company, obtained an exclusive license from GHDDI to develop, manufacture and commercialize the anti-SARS-CoV-2 new drug candidate GDI-4405 series worldwide. ABOUT HS-10517: HS-10517 (belong to GDI-4405 series) is an oral small molecule 3CL protease inhibitor against SARS-CoV-2. HS-10517 exhibits high potent antiviral activity on SARS-CoV-2 delta and omicron variants.